Kinan Alhallak
Kinan Alhallak
Brigham and Women's Hospital
Verified email at
Cited by
Cited by
Optical redox ratio identifies metastatic potential-dependent changes in breast cancer cell metabolism
K Alhallak, LG Rebello, TJ Muldoon, KP Quinn, N Rajaram
Biomedical optics express 7 (11), 4364-4374, 2016
Targeting CD47 as a novel immunotherapy for multiple myeloma
J Sun, B Muz, K Alhallak, M Markovic, S Gurley, Z Wang, N Guenthner, ...
Cancers 12 (2), 305, 2020
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
P de la Puente, MJ Luderer, C Federico, A Jin, RC Gilson, C Egbulefu, ...
Journal of Controlled Release 270, 158-176, 2018
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
C Federico, K Alhallak, J Sun, K Duncan, F Azab, GP Sudlow, ...
Nature communications 11 (1), 1-13, 2020
Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile
C Federico, J Sun, B Muz, K Alhallak, PF Cosper, N Muhammad, A Jeske, ...
International Journal of Radiation Oncology* Biology* Physics 109 (5), 1483-1494, 2021
A radiosensitizing inhibitor of HIF-1 alters the optical redox state of human lung cancer cells in vitro
DE Lee, K Alhallak, SV Jenkins, I Vargas, NP Greene, KP Quinn, ...
Scientific reports 8 (1), 1-10, 2018
Thermal sensitive liposomes improve delivery of boronated agents for boron neutron capture therapy
MJ Luderer, B Muz, K Alhallak, J Sun, K Wasden, N Guenthner, ...
Pharmaceutical research 36 (10), 1-8, 2019
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
K Alhallak, J Sun, K Wasden, N Guenthner, J O’Neal, B Muz, J King, ...
Leukemia 35 (8), 2346-2357, 2021
Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells
K Alhallak, SV Jenkins, DE Lee, NP Greene, KP Quinn, RJ Griffin, ...
Journal of Biomedical Optics 22 (6), 060502, 2017
Quantitative diffuse reflectance spectroscopy of short-term changes in tumor oxygenation after radiation in a matched model of radiation resistance
PM Diaz, SV Jenkins, K Alhallak, D Semeniak, RJ Griffin, RPM Dings, ...
Biomedical Optics Express 9 (8), 3794-3804, 2018
Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges
K Alhallak, J Sun, A Jeske, C Park, J Yavner, H Bash, B Lubben, ...
Cancers 13 (12), 2853, 2021
Rapid quantification of mitochondrial fractal dimension in individual cells
I Vargas, K Alhallak, OI Kolenc, SV Jenkins, RJ Griffin, RPM Dings, ...
Biomedical Optics Express 9 (11), 5269-5279, 2018
CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia
B Muz, N Bandara, C Mpoy, J Sun, K Alhallak, F Azab, BE Rogers, ...
Cancer biology & therapy 21 (1), 52-60, 2020
Biomaterials for cancer immunotherapy
K Alhallak, J Sun, B Muz, AK Azab
Biomaterials for Cancer Therapeutics, 499-526, 2020
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
K Alhallak, A Jeske, P de la Puente, J Sun, M Fiala, F Azab, B Muz, ...
Scientific reports 11 (1), 1-10, 2021
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia
K Alhallak, J Sun, B Muz, A Jeske, J Yavner, H Bash, C Park, B Lubben, ...
Oncotarget 12 (19), 1878, 2021
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance
K Alhallak, P de la Puente, A Jeske, J Sun, B Muz, MP Rettig, I Sahin, ...
Leukemia & Lymphoma 62 (10), 2457-2465, 2021
Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
K Alhallak, J Sun, B Muz, A Jeske, J O’Neal, JK Ritchey, S Achilefu, ...
Journal of Cellular and Molecular Medicine 26 (3), 940-944, 2022
A Novel Innovation and Entrepreneurship (I&E) Training Program for Biomedical Research Trainees
JG Grailer, K Alhallak, AL Antes, MS Kinch, L Woods, E Toker, JM Garbutt
Academic Medicine 97 (9), 1335-1340, 2022
T cell engaging agents and methods of use thereof
AK Azab, K Alhallak
US Patent App. 16/698,285, 2020
The system can't perform the operation now. Try again later.
Articles 1–20